On the contrary, SET7/9 inhibitors are suggested to be new therapeutic strategies for hormone-dependent breast cancers, such as ERa-positive ones [13, 39], even though there have been no reports on the SET7/9 mutation and expression change in primary breast cancer. This evidence concerns the gene ESR1 and breast cancer.